Peptisource

Semaglutid 5mg

Semaglutid is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist widely used in the treatment of type 2 diabetes. By mimicking the actions of native GLP-1, it promotes glucose-dependent insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite, thereby achieving glycemic control and weight management. Its half-life of seven days supports once-weekly subcutaneous administration, significantly improving patient medication adherence. Clinical trials have demonstrated that this drug can reduce glycated hemoglobin (HbA1c) levels with a very low risk of hypoglycemia, while also lowering the risk of cardiovascular events. Beyond diabetes management, semaglutide is indicated for obesity management and is currently being investigated for its potential efficacy in non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease. This therapeutic approach with a dual mechanism of action—targeting both glycemic regulation and metabolic parameters—provides comprehensive metabolic benefits, significantly enhancing the treatment outcomes for chronic metabolic disorders.

Spec: 5mg
Packaging: 1kits（10Vials）
$80USD
1

▎What is Semaglutid?


Semaglutid is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist widely used in the treatment of type 2 diabetes. By mimicking the actions of native GLP-1, it promotes glucose-dependent insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite, thereby achieving glycemic control and weight management. Its half-life of seven days supports once-weekly subcutaneous administration, significantly improving patient medication adherence. Clinical trials have demonstrated that this drug can reduce glycated hemoglobin (HbA1c) levels with a very low risk of hypoglycemia, while also lowering the risk of cardiovascular events. Beyond diabetes management, semaglutide is indicated for obesity management and is currently being investigated for its potential efficacy in non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease. This therapeutic approach with a dual mechanism of action—targeting both glycemic regulation and metabolic parameters—provides comprehensive metabolic benefits, significantly enhancing the treatment outcomes for chronic metabolic disorders.